Steinblanton6050
Disturbances in sleep and wakefulness are important symptoms of Parkinson's disease (PD) and are associated with negative effects on patients' quality of life. The analysis of literature on the relationship between RLS and PD revealed three main hypotheses explaining the relatively high incidence of RLS in PD (1) RLS can be considered as an early (prodromal) manifestation or a predictor of PD that can outpace its main symptoms by several years (by analogy with conduct disorder during sleep with REM); (2) the high incidence of RLS in the advanced stage of PD may be associated with augmentation of previously latent RLS symptoms during prolonged dopaminergic therapy of PD; (3) a significant proportion of RLS cases in PD patients are not «classical» RLS, but represent, for example, manifestations of motor or non-motor fluctuations or a special form of stereotypy in the legs. Further research is needed to determine if any of these statements are true.The asymmetry of motor symptoms in Parkinson's disease (PD) reflects the asymmetry of the degenerative process and death of nigrostriatal dopaminergic neurons in the substantia nigra, which is confirmed by the data of functional neuroimaging. DNA-PK inhibitor This review discusses a possible effect of the asymmetry of substantia nigra lesions on other PD symptoms, primarily neuropsychological functions. The authors summarize the data obtained in a comparative analysis of cognitive impairments in PD patients with right-sided and left-sided predominance of motor symptoms. The association between the asymmetry of motor and cognitive symptoms indicates the variability of the profile of cognitive impairments in PD, as well as an important modulating role of subcortical structures on neuropsychological functions traditionally referred to as cortical. The effect of lateralization of symptoms on cognitive function should be considered when evaluating and treating PD patients.Neuroendocrine and neurometabolic disorders, although occasionally noted in Parkinson's disease (PD), existed in the shadow of motor and non-motor symptoms (hypokinesia, rigidity, tremor, depression, constipation, etc.). In recent years, they are increasingly being diagnosed and are the subject of special research. These include, in particular, disorders of carbohydrate metabolism, changes in body weight, metabolic disorders in bone tissue, secretion, as well as the secretion of neurohormones, such as melatonin. They are associated with other non-motor symptoms, negatively affect patients' general condition and quality of life, but can be treatable. At the same time, treatment of neuroendocrine and neurometabolic disorders can favorably influence the rate of progression of the disease as a whole. This review discusses the pathophysiological mechanisms, clinical consequences, as well as pharmacological and non-pharmacological approaches to the treatment of neuroendocrine and neurometabolic disorders arising in PD, which have been relatively rarely covered in literature.
To study clinical and neurophysiological features of speech disorders in PD, multisystem atrophy (MSA) and progressive supranuclear palsy (PNP).
Thirty-one patients with PD and 14 patients with MSA and PSP were examined. The Unified rating scale for Parkinson's disease of the International movement disorders society (MDS-UPDRS) and a neurophysiological analysis of speech disorders using acoustic spectral analysis of voice and speech according to the method of Jan Rusz et al (2004) were used.
Patients with PD showed a parallel increase in the severity of axial motor disorders (hypomimia, walking disorders, postural disorders) and speech disorders. Patients with MSA and PSP differ not only from the PD patients but also among themselves by clinical presentations (motor, autonomic, cognitive) and speech disorders.
The clinical and neurophysiological features of speech disorders in patients with various variants of parkinsonism will be useful in the differential diagnosis of these diseases and can be used in developing approaches to patient rehabilitation.
The clinical and neurophysiological features of speech disorders in patients with various variants of parkinsonism will be useful in the differential diagnosis of these diseases and can be used in developing approaches to patient rehabilitation.Heart failure is one of the most frequent causes predisposing to cognitive impairment where its prevalence varies from 25 to 80% of cases. In this review, the mechanisms of microcirculatory abnormalities, which play a potential role in the development of cognitive impairment in patients with heart failure, are considered. Understanding of these mechanisms will help in the development of targeted therapy of cardiovascular and cerebrovascular diseases.
Comparative evaluation of the effectiveness and safety of antidepressant monotherapy and combined antidepressant therapy with the inclusion of neuroprotectors in the treatment of depression in old and very old patients in a psychiatric hospital.
The study included 2 groups of patients from the cohort of patients hospitalized in the gerontopsychiatric unit with mild and moderate depression (according to the ICD-10 classification) aged 60 years and older. The groups are comparable in their main demographic and clinical characteristics. Both groups received antidepressant monotherapy with venlafaxine (21 people) or combined therapy with the same antidepressant, but in combination with cerebrolysin or carnicetine (40 people) for 8 weeks. The efficacy of antidepressant therapy was evaluated with HAMD-17 and HARS; the effect of treatment on the level of cognitive activity of patients with MMSE and the 10-word memory test.
In the group of patients receiving combined antidepressant therapy, a significantly fastnicetine can be recommended for use in a psychiatric hospital to improve the quality of the therapeutic response and reduce the time of hospitalization.
Combined antidepressant therapy with a combination of treatment with an antidepressant and a drug with neuroprotective properties can increase the effectiveness of antidepressant therapy in old and very old patients. Both cerebrolysin and carnicetine can be recommended for use in a psychiatric hospital to improve the quality of the therapeutic response and reduce the time of hospitalization.
